Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

Gastric Cancer Clinical Trial

— a-MANTRA  

Official title:

Phase II Randomized Study of Maintenance Regorafenib vs Placebo in no Progression Patients After First-line Platinum and Fluoropyrimidines Based Chemotherapy in HER2 Negative Locally Advanced/Metastatic Gastric or Gastroesophagel Junction Cancer (a-MANTRA Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03627728
• Other study ID #: GOIRC-05-2016
• Status: Recruiting
• Phase: Phase 2
• Start date: June 13, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: August 2022
• Source: Gruppo Oncologico Italiano di Ricerca Clinica
• Contact: Carmine pinto, MD
• Phone: +390522296614
• Email: carmine.pinto[@]ausl.re.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, double-blind, placebo-controlled, multicenter Phase-II study. Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or capecitabine, up to 12 cycles of FOLFOX, up to 8 cycles of XELOX, will be randomly assigned (1:1 ratio) to one of the following treatment groups: Arm A: Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease Arm B: Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease Primary Variable: PFS1

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2022
• Est. primary completion date: June 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male of female = 18 years of age

2. Have an Eastern Cooperative Oncology Group performance status of 0 or 1 within 14 days prior to the initiation of study treatment

3. Diagnosis of histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction

4. HER2 negative gastric or gastroesophagel junction cancer ( ICH 0, IHC 1+, IHC + FISH -)

5. Locally advanced/metastatic gastric or gastroesophageal junction cancer

6. CR/PR/SD after first-line platinum compound and Fluoropyrimidines based chemotherapy

7. Measurable disease according to RECIST 1.1 criteria

8. Have adequate bone marrow function, liver function, and renal function, as measured by the following laboratory assessments conducted within 7 days prior to the initiation

of study treatment:

9. Total bilirubin 1.5 times the upper limit of normal (ULN)

10. Alanine aminotransferase and aspartate aminotransferase 3 times the ULN

11. Lipase 1.5 times the ULN

12. Serum creatinine 1.5 times the ULN

13. Glomerular filtration rate 30 mL/min/1,73 m2 according to the Modified Diet in Renal Disease abbreviated formula

14. International normalized ratio of prothrombin time and activated partial thromboplastin time 1.5 times the ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no underlying abnormality in coagulation parameters exists per medical history.

15. Platelet count 100,000 /mm3, hemoglobin 9 g/dL, absolute neutrophil count 1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factors

16. Alkaline phosphatase = 2.5 times the ULN

17. Understand, be willing to give consent, and sign the written informed consent form (ICF) prior to undergoing any study-specific procedure.

18. If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment.

19. If female and of childbearing potential, or if male, agree to use adequate contraception (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 8 weeks after the last dose of study drug.

Exclusion Criteria:

1. Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)

2. Have used biologic response modifiers, such as G-CSF, within 3 weeks of study entry

3. Have had prior treatment with regorafenib or any other VEGFR-targeting kinase inhibitor.

4. Completed their last dose of chemotherapy more than 8 weeks, whichever came later, prior to randomization.

5. Have had prior or concurrent cancer distinct in primary site or histology from GC or GJC within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, no-melanoma skin cancer, or superficial bladder tumors classified as noninvasive tumor (Ta), carcinoma in situ (Tis), or tumor invades lamina propria (T1).

6. Have had systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation of study treatment.

7. Have unresolved toxicity higher than National Cancer Institute-Common Terminology for Adverse Events version 4.0 (NCI-CTCAE v 4.0) Grade 1 attributed to any prior therapy/procedure, excluding alopecia and/or oxaliplatin-induced neurotoxicity = Grade 2 and hemoglobin = 9 g/dL as per inclusion criteria

8. Have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment.

9. Are pregnant.

10. Are breastfeeding.

11. Are unable to swallow oral tablets (crushing of study treatment tablets is not allowed).

12. Have congestive heart failure classified as New York Heart Association Class 2 or higher

13. Have had unstable angina (angina symptoms at rest) or new-onset angina 3 months prior to screening.

14. Have had a myocardial infarction 6 months prior to initiation of study treatment.

15. Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin.

16. Have uncontrolled hypertension (systolic blood pressure [SBP] 140 mmHg or diastolic blood pressure [DBP] 90 mmHg) despite optimal medical management.

17. Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months prior to the initiation of study treatment.

18. Have an ongoing infection with severity of Grade 2 or above (NCI-CTCAE v 4.0).

19. Have a known history of human immunodeficiency virus infection.

20. Have either active or chronic hepatitis B or C requiring treatment with antiviral therapy.

21. Have a seizure disorder requiring medication.

22. Have a history of organ allograft.

23. Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.

24. Have had a hemorrhage or a bleeding event Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment.

25. Have a nonhealing wound, ulcer, or bone fracture.

26. Have renal failure requiring hemodialysis or peritoneal dialysis.

27. Have dehydration Grade 1 (NCI-CTCAE v 4.0).

28. Have interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained.

29. Have persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.0).

30. Have any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results.

31. Have a known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs.

32. Have any malabsorption condition.

33. Have a close affiliation with the investigational site (eg, be a close relative of the investigator) or be a dependent person (eg, be an employee or student working at the investigational site).

34. Untreated gastro-esophageus varices

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Regorafenib
regorafenib/placebo

Other:
• placebo
regorafenib/placebo

Locations

Country	Name	City	State
Italy	Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova	Reggio Emilia

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Oncologico Italiano di Ricerca Clinica

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS1	Progression free survival will be calculated for all patients from the date of randomization until the date PD or death is first reported.	36 months
Secondary	OS	time from date of randomization to the date of Death from any cause	36 months
Secondary	PFS2	PFS 2 will be calculated from the start of second line therapy to PD or death	36 months
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability	The overall incidences of AEs will be summarized. Patients who experienced the same event on more than one occasion are counted only once in the calculation of the event frequency, at the highest intensity ever observed.	36 months
Secondary	Response Rate	in patients who are randomized at enrollment to treatment with regorafenib vs placebo,	36 months
Secondary	quality of life To compare the patient treatment-related symptoms	To compare the patient treatment-related symptoms as measured by the European Organization for research and treatment of cancer EORTC QLQ-C30, (days 1, week , 8, 16, 24, 32) , for patients in each treatment arm.	up to 8 months
Secondary	biomarker evaluation	To correlate the genetic mutational profile of the tumors with the RR and the OS of the patients	36 months